Please ensure Javascript is enabled for purposes of website accessibility

Here's How AbbVie Impressed Investors With Its Q4 Update

By Keith Speights - Updated Feb 7, 2020 at 5:27PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The big drugmaker didn't just beat Wall Street estimates in Q4. It provided better-than-expected 2020 guidance, too.

AbbVie (ABBV 0.53%) hasn't been delivering the kind of stock performance that investors like. But the drugmaker continues to beat expectations with its financial results. In November, the company reported a surprisingly solid performance with its third-quarter results. And now AbbVie has done it again.

The company announced its 2019 fourth-quarter and full-year results before the market opened on Friday. AbbVie's shares jumped 5% in early trading, hinting at just how positively those results were received by investors. Here are the highlights from big pharma company's Q4 update.

Pill capsule with small, gold dollar signs coming out on top of lots of white, round pills

Image Source: Getty Images.

By the numbers

AbbVie reported fourth-quarter revenue of $8.7 billion, a solid 5% year-over-year increase. This result also narrowly beat the consensus Wall Street revenue estimate of $8.69 billion. 

The company's bottom-line improvement was even better. AbbVie announced Q4 earnings of $2.8 billion, or $1.88 per share, based on generally accepted accounting principles (GAAP). It posted a GAAP loss of $1.83 billion, or $1.23 per share, in the prior-year period.

AbbVie's adjusted earnings per share (EPS) jumped 16% year over year to $2.21 in the fourth quarter. This result topped the average analysts' estimate of Q4 adjusted earnings per share of $2.19.

Behind the numbers

Anytime AbbVie provides a quarterly update, what happened with Humira is usually the biggest story. For Humira, though, there are really two stories. In the U.S., sales of Humira jumped 9.8% year over year to $3.97 billion. However, international sales for the immunology drug fell by 27.3% to $948 million as Humira battles biosimilar rivals. Overall, sales for Humira were basically flat year over year at $4.92 billion.

Imbruvica is becoming an even bigger factor in AbbVie's performance. Sales for the cancer drug soared 28.9% year over year in Q4 to $1.3 billion. Another cancer drug in AbbVie's lineup, Venclexta, appears to be on the way to becoming a blockbuster, with Q4 sales of $251 million.

AbbVie's new immunology drugs Rinvoq and Skyrizi also performed well. Sales for Rinvoq totaled $33 million in the drug's first full quarter on the market. Skyrizi sales more than doubled quarter over quarter to $216 million.

However, there were some problem areas. Sales for AbbVie's hepatitis C virus (HCV) franchise declined 26.7% year over year to $632 million. Combined sales for its other key products, including Creon, Lupron, and Synagis, slipped 3.8% year over year to $1.29 billion.

Looking ahead

AbbVie projects full-year 2020 GAAP diluted earnings per share will be between $7.66 and $7.76. The company expects adjusted EPS will be between $9.61 and $9.71, an 8.1% year-over-year increase at the midpoint of the range. This guidance was better than the average analysts' full-year 2020 adjusted EPS estimate of $9.48.

This positive outlook is no doubt fueled in large part by the success of AbbVie's new drugs. CEO Richard Gonzalez said, "The launches of Skyrizi and Rinvoq are going extremely well, and we are entering 2020 with substantial momentum."

The most important thing for investors to watch for with AbbVie is the anticipated closing of its acquisition of Allergan later in the first quarter of 2020. AbbVie already ranks as one of the most attractive dividend stocks on the market. The company thinks that its purchase of Allergan will help it deliver solid growth in the future as well.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$153.14 (0.53%) $0.80
Allergan plc Stock Quote
Allergan plc
AGN

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.